sunitinib pfizer
pfizer new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25mg; - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25mg excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma
sunitinib (rex)
rex medical ltd - sunitinib malate 33.4mg equivalent to sunitinib 25 mg - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25 mg excipient: croscarmellose sodium gelatin iron oxide red iron oxide yellow magnesium stearate mannitol povidone purified water titanium dioxide - indicated for: - treatment of advanced renal cell carcinoma. - treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesylate treatment due to resistance or intolerance. - treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).
sunitinib dr.reddy's
dr reddy's new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25 mg - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25 mg excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide water - treatment of advanced renal cell carcinoma treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net)
sutent
pfizer new zealand limited - sunitinib malate 33.4mg equivalent to 25 mg sunitinib; - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to 25 mg sunitinib excipient: croscarmellose sodium gelatin iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone propylene glycol shellac sodium hydroxide sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.
sutent sunitinib (as malate) 25 mg capsule blister pack
pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: sodium hydroxide; titanium dioxide; mannitol; shellac; sodium lauryl sulfate; iron oxide red; propylene glycol; povidone; croscarmellose sodium; magnesium stearate; gelatin; iron oxide black; iron oxide yellow - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).
sunitinib malate capsule
dr.reddys laboratories inc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summarybased on animal reproduction studies and its mechanism of action, sunitinib malate can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to
sutent sunitinib (as malate) 25 mg capsule bottle
pfizer australia pty ltd - sunitinib malate, quantity: 33.4 mg (equivalent: sunitinib, qty 25 mg) - capsule - excipient ingredients: titanium dioxide; mannitol; propylene glycol; shellac; sodium lauryl sulfate; povidone; iron oxide yellow; iron oxide red; sodium hydroxide; magnesium stearate; croscarmellose sodium; iron oxide black; gelatin - sutent is indicated for: ? treatment of advanced renal cell carcinoma (rcc) ? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance ? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).
sunitinib malate capsule
mylan pharmaceuticals inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregnant rats and
sunitinib malate capsule
sun pharmaceutical industries inc. - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none. risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregn
sunitinib malate capsule
northstar rxllc - sunitinib malate (unii: lvx8n1ut73) (sunitinib - unii:v99t50803m) - sunitinib malate capsules are indicated for the treatment of adult patients with gastrointestinal stromal tumor (gist) after disease progression on or intolerance to imatinib mesylate. sunitinib malate capsules are indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc). sunitinib malate capsules are indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy. sunitinib malate capsules are indicated for the treatment of progressive, well differentiated pancreatic neuroendocrine tumors (pnet) in adult patients with unresectable locally advanced or metastatic disease. none risk summary based on animal reproduction studies and its mechanism of action, sunitinib can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . there are no available data in pregnant women to inform a drug-associated risk. in animal developmental and reproductive toxicology studies, oral administration of sunitinib to pregna